Site icon news.soban.in

HAB Pharma targets ₹3,000 crore revenue by 2030 after merger deal(Soban News)

HAB Pharmaceuticals aims to scale operations and expand globally after merging with Signature Phytochemical Industries through a slump sale deal

​HAB Pharmaceuticals aims to scale operations and expand globally after merging with Signature Phytochemical Industries through a slump sale deal by Soban News (international And National News)

Exit mobile version